- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Endomagnetics is pleased to announce it has reached an agreement with Aurora BioScience as its exclusive distributor for Australia and New Zealand. This appointment significantly extends the availability of the company's SentiMag® and Sienna+® tracer system. Breast cancer patients in the region will now have access to new technology that optimally locates lymph nodes as part of the cancer staging procedure in Sentinel Lymph Node Biopsy (SLNB).
Current standard-of-care for SLNB requires a radioactive isotope injection, which has limited availability in Australia and New Zealand. The SentiMag system increases the availability of the standard-of-care and also improves workflow, putting the surgeon in control of tracer injection. The system has been used in 10 clinical studies and trials with over 1,500 patients across 12 European countries since 2012. The first two trials have published recently, and demonstrated clinical equivalence to the standard-of-care.
Aurora Bioscience is exclusively responsible for the sales, marketing and distribution of the SentiMag® system in the Australian and New Zealand markets. Aurora is a leading specialist distributor of high technology medical devices across fields including oncology, blood technology, respiratory medicine and neurology. It provides a service to metropolitan and regional areas across Australia and New Zealand and around the Pacific Islands.
Mathew Stephens, Director of Sales and Business Development at Endomagnetics said: "We are delighted to be working with the team at Aurora as this appointment significantly strengthens our distribution in this key geographical market. The interest from Australian and New Zealand surgeons has been huge and we are looking forward to developments in the coming months."
For Aurora BioScience, Darren Banks, Managing Director said: "The Endomagnetics technology is a perfect fit with our advanced, innovative range of medical devices, and the technology will significantly improve patient experience by extending availability of the SLNB technique".
Endomagnetics Ltd was founded to solve cancer staging and healthcare challenges through the application of advanced magnetic sensing technology and nanotechnology. Endomagnetics is developing a portfolio of medical device products based on a patented ability to detect magnetic materials in the human body with exceptional sensitivity. The technology was originally developed at University College London and the University of Houston.
The company’s first product, the SentiMag®, is an ultrasensitive hand-held probe for tracking injected Sienna+® nanoscale magnetic materials in the human body. Cambridge, UK-based Endomagnetics is in the process of delivering its technology to global markets.
About Aurora BioScience
Located in Sydney Australia, Aurora BioScience Pty Ltd is committed to providing advanced, high quality medical devices and healthcare products to assist medical professionals within Australia, New Zealand and the Pacific Islands healthcare markets, to contribute to the enhancement of patient’s quality of life. Areas of interest include cancer therapies, neurology, pulmonology, and haematology and blood products.
For more information, please visit www.aurorabioscience.com.au
For more information, please click here
Tel: +44 (0)7923 540695
Dr Eric Mayes, CEO
Tel: +44 (0)1223 652540
Copyright © EndomagneticsIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Stealth nanocapsules kill Chagas parasites in mouse models June 22nd, 2016
FEI and University of Liverpool Announce QEMSCAN Research Initiative: University of Liverpool will utilize FEI’s QEMSCAN technology to gain a better insight into oil and gas reserves & potentially change the approach to evaluating them June 22nd, 2016
French Research Team Helps Extend MRI Detection of Diseases & Lower Health-Care Costs: CEA, INSERM and G2ELab Brings Grenoble Region’s Expertise In Advanced Medicine & Magnetism Applications to H2020 IDentIFY Project June 21st, 2016